2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
581
Carboplatin
528
Cisplatin
359
Bevacizumab
256
pembrolizumab
228
Gemcitabine
157
liposomal doxorubicin
132
Topotecan
131
olaparib
129
Cyclophosphamide
128
Radiotherapy
118
Taxes
114
Docetaxel
95
Brachytherapy
94
Drug Therapy
91
niraparib
88
Doxorubicin
86
Surveys and Questionnaires
85
Magnetic Resonance Spectroscopy
80
Blood Specimen Collection
74
Nivolumab
71
Specimen Handling
70
Hyperthermic Intraperitoneal Chemotherapy
64
Biopsy
63
fludarabine
57
Filgrastim
53
Letrozole
50
Oxaliplatin
49
durvalumab
47
Immunoglobulin G
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
nanocis
×
Gynecologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled
NCT02667925
2016-10-11
ISOTOVE
Centre Jean Perrin
Phase NA
Withdrawn